Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes

Author： Zhang J. Tokui Y. Yamagata K. Kozawa J. Sayama K. Iwahashi H. Okita K. Miuchi M. Konya H. Hamaguchi T. Namba M. Shimomura I. Miyagawa J-i.

Publisher： Springer Publishing Company

ISSN： 0012-186X

Source： Diabetologia, Vol.50, Iss.9, 2007-09, pp. : 1900-1909

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Potentiation and prolongation of the insulinotropic action of glucagon-like peptide 1 by methyl pyruvate or dimethyl ester of l-glutamic acid in a type 2 diabetes animal model

By Cancelas Jesús Villanueva-Peñacrrillo María Valverde Isabel Malaisse Willy

Endocrine Journal, Vol. 16, Iss. 2, 2001-11 ,pp. : 113-116

Humana Press, Inc

Access to resources Recommend Favorite

Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus

By Gallwitz Baptist

Treatments in Endocrinology, Vol. 4, Iss. 6, 2005-01 ,pp. : 361-370

Adis International

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy

Current Diabetes Reviews, Vol. 12, Iss. 4, 2016-10 ,pp. : 403-413

Bentham Science Publishers

Access to resources Recommend Favorite

CD14 triggers autoimmune Type 1 diabetes in the NOD mouse

By Klöting N. Klöting I. Jack R.

Diabetologia, Vol. 47, Iss. 1, 2004-01 ,pp. : 151-152

Springer Publishing Company

Access to resources Recommend Favorite

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

By Hogan Andrew Gaoatswe Gadintshware Lynch Lydia Corrigan Michelle Woods Conor O’Connell Jean O’Shea Donal

Diabetologia, Vol. 57, Iss. 4, 2014-04 ,pp. : 781-784

Springer Publishing Company

Access to resources Recommend Favorite